Prognostic Factors in Non-Hodgkin's Lymphoma
Author Information
Author(s): R.A. Cowan, M. Jones, M. Harris, W.P. Steward, J.A. Radford, J. Wagstaff, D.P. Deakin, D. Crowther
Primary Institution: Christie Hospital and Holt Radium Institute
Hypothesis
What factors can predict survival in patients with high and intermediate grade non-Hodgkin's lymphoma?
Conclusion
The study identifies several important prognostic factors, including remission status and clinical stage, that can help predict survival in patients with non-Hodgkin's lymphoma.
Supporting Evidence
- 65% of patients achieved complete remission, which is the most important predictor of survival.
- Patients with advanced clinical stage and elevated serum LDH had poorer survival outcomes.
- The study confirms the significance of the Ann Arbor staging system in assessing prognosis.
Takeaway
Doctors can better understand how likely patients with non-Hodgkin's lymphoma are to survive by looking at their remission status and the stage of their disease.
Methodology
The study analyzed data from 260 patients treated over 11 years, using univariate and multivariate analyses to assess prognostic factors.
Limitations
The study is retrospective and may be limited by the data collection methods and the time frame of treatment.
Participant Demographics
Patients aged 15-75 years, with no previous treatment for NHL or history of malignancy.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website